research 12 Treatment of hirsutism with 5α-reductase inhibitors
New compounds may soon be tested to treat excessive hair growth in women.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
research Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
research Identification of Metabolites for the Novel 5α‐Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing
Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
research Bioprospecting of Potential Inhibitors of 5alpha Reductase 2 Inhibitors from Relevant Ethno-pharmacological Plants via In Silico Techniques
Three natural compounds from Ghanaian plants may help treat BPH and alopecia.
research Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
research O que sabemos sobre os inibidores da 5 alfa redutase?
Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
research Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
research Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations
A new compound may treat benign prostatic hyperplasia better than finasteride.
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.